METTL3 inhibitor sTC-15 treats acute myeloid leukemia.

Acute myeloid leukemia (AML) is the most common type of leukemia in adults, but it can affect people of all ages.
, AML is caused by chemotherapy or radiotherapy used to treat another cancer.
in AML, immature leukemia cells quickly gather in the bone marrow, destroying and replacing normal hematocytes.
leukemia cells are released into the bloodstream and transported to other organs, where they continue to grow and divide.
, a spin-off company at the University of Cambridge, announced that its state-of-the-art METTL3 inhibitors are in clinical trials.
STC-15 is an oral small molecule METTL3 inhibitor used to treat acute myeloid leukemia and other solid and blood cancers.
company uses its drug discovery capabilities, as well as analytical techniques developed specifically for RNA oscic genetics, to produce highly effective selective small molecule inhibitors for METTL3 and other RNA modifier enzymes.
The sTC-15 is an efficient and selective METTL3 inhibitor, and patients with acute myeloid leukemia will be included in the initial clinical trials," said Keith Blundy, CEO of STORM Therapeutics.
.